Interleukin ۶ but not Interleukin ۸ Might be an Indicator of Multiple Sclerosis Progression from Relapse Remitting to Secondary Progressive Status
Publish place: Research in Molecular Medicine، Vol: 8، Issue: 1
Publish Year: 1398
نوع سند: مقاله ژورنالی
زبان: English
View: 37
This Paper With 8 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_REMJ-8-1_001
تاریخ نمایه سازی: 20 دی 1402
Abstract:
Background: Multiple Sclerosis (MS) is the most common chronic inflammatory disease of the white matter of the Central Nervous System (CNS). Proinflammatory cytokine network such as interleukin-۶ (IL-۶) has a role in the initiation of a destructive immune response in CNS and the progression of the disease. This study aimed to evaluate the comparative levels of IL-۶ and IL-۸ in MS patients and healthy controls and also to assess any fluctuation in IL-۶ and IL-۸ levels in MS progression.
Materials and Methods: This case-control study recruited a total of ۱۸۳ subjects, including ۱۰۳ MS patients and ۸۰ sex- and age-matched healthy controls. MS patients included ۵۱ Relapsing Remitting MS (RRMS), ۲۵ secondary progressive MS (SPMS), ۲۷ Primary Progressive MS (PPMS), and Progressive Relapsing MS (PRMS). Clinical findings were collected, and serum levels of IL-۶, IL-۸, and ۲۵-hydroxyl vitamin D۳ (۲۵(OH)D۳) were determined with ELISA.
Results: The mean serum level of IL-۶ was significantly higher in MS patients than healthy controls (۲۳.۸±۲.۱ vs. ۱۵.۶±۲.۷ pg/mL, P=۰.۰۴۳). MS patients with SPMS had more prominent IL-۶ levels than RRMS or PPMS (P=۰.۰۰۸). However, IL-۸ levels did not show a significant change either in the
patients compared with the controls or in the different forms of MS. MS was more prone to progressive form in male patients. Mean ۲۵(OH)D۳ level was significantly lower in MS patients than the controls. Meanwhile, the mean ۲۵(OH)D۳ level was surprisingly higher in MS patients with SPMS.
Conclusion: The increased serum level of IL-۶ in more advanced MS status, SPMS, suggests that IL-۶ but not IL-۸ might be a prognostic marker for the disease deterioration. Besides, the tendency for MS to progress to worse stages in affected men is an important finding that needs further clarification.
Keywords:
Multiple Sclerosis , Interleukin-۶ (IL-۶) , Interleukin-۸ (IL-۸) , ۲۵-Hydroxyl vitamin D۳ , Clinical symptoms , Secondary progressive MS (SPMS) , Relapsingremitting MS (RRMS)
Authors
Mina Eslami
MSc Student of Immunology, Student Research Committee Mazandaran University of Medical Sciences, Sari, Iran
Araz Mohammad Mirabi
Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
Mohammad Baghbanian
Department of Neurology, Booalisina Hospital, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
Alireza Rafiei
Department of Immunology, Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :